GlassScriptPhysician profile
Matthew Dacunha
NPI 1659833622
$2,373.77
in general payments reported to CMS, 2019-2025
19 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.00 · 2023: $23.44 · 2024: $461 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.62 | 2024-2025 | |
| Amgen INC. | $268.77 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $224.52 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.21 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $162.04 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $125.70 | 2024-2025 | Adbry |
| Ucb, INC. | $123.52 | 2023-2025 | Bimzelx, Cimzia |
| Almirall LLC | $121.04 | 2024-2025 | Seysara |
| Kerecis Limited | $113.39 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mayne Pharma Commercial LLC | $113.32 | 2025 | |
| Incyte Corporation | $98.79 | 2025 | Opzelura |
| Pfizer INC. | $77.56 | 2025 | |
| Galderma Laboratories, L.P. | $75.03 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $58.33 | 2025 | Tremfya |
| Lilly USA, LLC | $54.99 | 2025 | Taltz, Ebglyss |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $25.83 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.87 | 2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dacunha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.